Simon Tian

5.4k citations

32 papers · 1.0k indexed · h-index 13

Pulmonary and Respiratory Medicine top 2%
- Cystic Fibrosis Research Advances 26
- Neonatal Respiratory Health Research 7
- Tracheal and airway disorders 3
Emergency Medical Services top 5%
- Pediatric health and respiratory diseases 7
Speech and Hearing top 10%
Psychiatry and Mental health top 10%
Genetics
- Coagulation, Bradykinin, Polyphosphates, and Angioedema 1
Plant Science
- Nematode management and characterization studies 3
- Legume Nitrogen Fixing Symbiosis 1
Physiology
- Pain Mechanisms and Treatments 1

Co-authors: Gregory S. Sawicki Michael W. Konstan Mark Higgins David Waltz Gautham Marigowda Nataliya Volkova C Simard Diana Bilton
Cited by: Pulmonary and Respiratory Medicine Emergency Medical Services Speech and Hearing
Journals: Journal of Cystic Fibrosis (15 papers)The Lancet Respiratory Medicine (3 papers)American Journal of Respiratory and Critical Care Medicine (3 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Simon Tian

30 papers receiving 1.0k citations

Peers

Countries citing papers authored by Simon Tian

Since Specialization

Citations

This map shows the geographic impact of Simon Tian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Tian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Tian more than expected).

Fields of papers citing papers by Simon Tian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Tian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Tian. The network helps show where Simon Tian may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Simon Tian, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Simon Tian Line = papers co-authored together Simon Tian links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Suzetrigine, a Non-Opioid NaV1.8 Inhibitor for Treatment of Moderate-to-Severe Acute Pain: Two Phase 3 Randomized Clinical Trials Anesthesiology ·Todd Bertoch,S. P. Bychkov,田艳军,Daneshvari R. Solanki,Yonggang 勇刚 Wu 伍,P. Urbański,Lindsey O. Ragland,Matthew W. Swisher,Simon Tian,Xiaopeng Miao,Darin Correll,Paul A. Negulescu,Carmen Bozic,Scott G. Weiner	2025	11
2	Safety and Tolerability of the APOL1 Inhibitor, Inaxaplin, Following Single- and Multiple-ascending Doses in Healthy Adults SHILAP Revista de lepidopterología ·Ogo Egbuna,Vincent Audard,George Manos,Simon Tian,Bengt v. Hofstein,Glenn M. Chertow	2024	3
3	Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR : A Phase 2 Placebo-controlled Clinical Trial Annals of the American Thoracic Society ·Mirjam Stahl,Jobst Roehmel,Monika Eichinger,Felix Doellinger,Lutz Naehrlich,Matthias Kopp,Anna‐Maria Dittrich,Christopher Lee,Olaf Sommerburg,Simon Tian,Tu Xu,信彦河田,Aniket Joshi,Partha Pratim Ray,Margaret E. Duncan,Mark O. Wielpütz,Marcus Mall	2023	13
4	Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events American Journal of Respiratory and Critical Care Medicine ·Bonnie W. Ramsey,Christoph U. Correll,David R. DeMaso,Edward F. McKone,Elizabeth Tullis,Jennifer L. Taylor‐Cousar,Chenghao Chu,Nataliya Volkova,Neil Ahluwalia,David Waltz,Simon Tian,Marcus Mall	2023	26
5	A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR American Journal of Respiratory and Critical Care Medicine ·Jonathan H. Rayment,Fadi Asfour,Margaret Rosenfeld,Mark Higgins,Lingyun Liu,Alexandra Lefebvre,Hildegarde Paz-Díaz,Simon Tian,Linn Sirén Gustafsson,Susanna A. McColley	2022	20
6	Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment European Journal of Drug Metabolism and Pharmacokinetics ·Gunpreet AJ,Eric Bachman,Simon Tian,Neil Ahluwalia,Richard. actor Martínez,Harold S. Bernstein,A. Ghosh	2022	13
7	Long-term safety and efficacy of lumacaftor–ivacaftor therapy in children aged 6–11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study The Lancet Respiratory Medicine ·Mark Chilvers,Jane C. Davies,Carlos Milla,Simon Tian,Dilip Kumar Pal,Alexandra G. Cornell,Caroline A. Owen,Félix Ratjen	2021	27
8	Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial American Journal of Respiratory and Critical Care Medicine ·Jane C. Davies,Claire Wainwright,Gregory S. Sawicki,Anastasia Rousaki,Daniel Campbell,Christopher Harris,A. Ghosh,Eric L. Haseltine,Simon Tian,Margaret Rosenfeld	2020	67
9	VO2max as an exercise tolerance endpoint in people with cystic fibrosis: Lessons from a lumacaftor/ivacaftor trial Journal of Cystic Fibrosis ·John Wilson,Xiaojun You,G. Lorini,Don S. Urquhart,Lokesh K. Jha,Michitsura Yoshiyama,Simon Tian,Ryan A. Harris,Tom Kotsimbos,D. Keating	2020	19
10	Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations Pulmonary Therapy ·Joseph M. Pilewski,K. De Boeck,Jerry A. Nick,Simon Tian,Cynthia DeSouza,Mark Higgins,Richard B. Moss	2020	6
11	WS19.2 Long-term safety of lumacaftor/ivacaftor therapy in persons with cystic fibrosis aged 2–5 years homozygous for the F508del-CFTR mutation (F/F) Journal of Cystic Fibrosis ·Jordana E. Hoppe,Mark Chilvers,Félix Ratjen,John McNamara,C.A. Owen,Simon Tian,Linn Sirén Gustafsson,Alexandra G. Cornell,Susanna A. McColley	2020	1
12	Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study The Lancet Respiratory Medicine ·John McNamara,Susanna A. McColley,Gautham Marigowda,Fang Liu,Simon Tian,Caroline A. Owen,David Stiles,Chonghua Li,David Waltz,Linda T. Wang,Gregory S. Sawicki	2019	102
13	An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2–5 years (KLIMB) Journal of Cystic Fibrosis ·Margaret Rosenfeld,Steve Cunningham,William T. Harris,Allen Lapey,Warren E. Regelmann,Gregory S. Sawicki,Kevin W Southern,Mark Chilvers,Mark Higgins,Simon Tian,Osada Hideyuki,Jane C. Davies	2019	90
14	Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries Journal of Cystic Fibrosis ·Nataliya Volkova,Kristin A. Moy,Jennifer Evans,Daniel Campbell,Simon Tian,C Simard,Mark Higgins,Michael W. Konstan,Gregory S. Sawicki,Alexander Elbert,Susan C. Charman,Bruce C. Marshall,Diana Bilton	2019	186
15	WS01.5 A 2-part, phase 3 single-arm study to evaluate the safety and pharmacokinetics (PK) of lumacaftor/ivacaftor (LUM/IVA) combination therapy in patients (pts) aged 2 to 5 years with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation Journal of Cystic Fibrosis ·John McNamara,Susanna A. McColley,C.A. Owen,Anyela Palavecino,Simon Tian,David Waltz,Gautham Marigowda,G. Sawicki	2018	1
16	Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor Thorax ·Leona Bessonova,Nataliya Volkova,Mark Higgins,Leif Bengtsson,Simon Tian,C Simard,Michael W. Konstan,Gregory S. Sawicki,A. Sewall,Stephen Nyangoma,Alexander Elbert,Bruce C. Marshall,Diana Bilton	2018	143
17	WS01.6 Preliminary safety and efficacy of triple combination CFTR modulator regimens in cystic fibrosis Journal of Cystic Fibrosis ·Jane C. Davies,Claudio Colombo,Elizabeth Tullis,Charlotte McKee,Cynthia DeSouza,David Waltz,J. R. K. Savage,M. Fisher,Rebecca A. Shilling,Samuel M. Moskowitz,みやえ山川,Simon Tian,Jennifer L. Taylor‐Cousar,Steven M. Rowe	2018	8
18	Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR Journal of Cystic Fibrosis ·Jennifer L. Taylor‐Cousar,Manu Jain,Jose Barrales-Ruiz,Tarik Haddad,Jeffrey J. Atkinson,Simon Tian,Rui Tang,Gautham Marigowda,David Waltz,Joseph M. Pilewski	2017	56
19	WS13.4 Efficacy and safety of lumacaftor/ivacaftor (LUM/IVA) in patients (pts) aged 6–11 years (yrs) with cystic fibrosis (CF) homozygous for F508del-CFTR: a randomized placebo (PBO)-controlled phase 3 trial Journal of Cystic Fibrosis ·Félix Ratjen,Simon Tian,Gautham Marigowda,Christopher Hug,Xin Huang,Sanja Stanojevic,Carlos Milla,Peter Robinson,David Waltz,Jane C. Davies	2017	10
20	Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study The Lancet Respiratory Medicine ·Michael W. Konstan,Edward F. McKone,Richard B. Moss,Gautham Marigowda,Simon Tian,David Waltz,Xiaohong Huang,Barry Lubarsky,Jaime Rubin,Stefanie J. Millar,David J. Pasta,Nicole Mayer-Hamblett,Christopher H. Goss,Wayne J. Morgan,Gregory S. Sawicki	2016	213

About Simon Tian

Simon Tian is a scholar working on Emergency Medical Services, Pulmonary and Respiratory Medicine and Nephrology, having authored 32 papers that have together received 1.0k indexed citations. Recurring topics across this work include Cystic Fibrosis Research Advances (26 papers), Pediatric health and respiratory diseases (7 papers), Neonatal Respiratory Health Research (7 papers), Nematode management and characterization studies (3 papers), Tracheal and airway disorders (3 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (1 paper), Pain Mechanisms and Treatments (1 paper) and Legume Nitrogen Fixing Symbiosis (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (989 citations), Emergency Medical Services (96 citations) and Speech and Hearing (51 citations). Simon Tian has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Gregory S. Sawicki, Michael W. Konstan, Mark Higgins, David Waltz, Gautham Marigowda, Nataliya Volkova, C Simard, Diana Bilton, Bruce C. Marshall and Alexander Elbert. Their work appears in journals such as Journal of Cystic Fibrosis, The Lancet Respiratory Medicine, American Journal of Respiratory and Critical Care Medicine, Journal of Clinical Oncology and Annals of the American Thoracic Society.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact